In NSCLC, about 3% of patients display a wide variety of mutations and deletions, all leading to skipping of MET exon 14 (METex14Del) [16, 32, 33, 34], encoding the negative regulatory juxtamembrane domain of the receptor. Here, MET is linked to non-small cell lung carcinoma.